The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

View More View Less
  • 1 From the Department of Gynecologic Oncology, Division of Surgery, City of Hope, Duarte, California.
  • 2 Assistant Managing Editor, Journal of the National Comprehensive Cancer Network
View More View Less
  • 1 From the Department of Gynecologic Oncology, Division of Surgery, City of Hope, Duarte, California.
  • 2 Assistant Managing Editor, Journal of the National Comprehensive Cancer Network

Ovarian cancer is the fifth most common cause of cancer-related death among women in the United States, although the median survival of patients has been increasing over the past few decades. In patients with epithelial ovarian cancer, chemotherapy has increased survival. Platinum agents combined with taxanes have become standard treatment. Intraperitoneal chemotherapy has also increased survival. Cytoreductive surgery to optimally debulk a tumor or, ideally, remove any gross disease has also been shown to increase survival. Each 10% increase in cytoreduction correlates with a 5.5% increase in median survival. The ability to successfully perform optimal cytoreduction ranges from 20% to 90%. Many institutions have recently begun to perform aggressive/ultraradical procedures to achieve this result. Interval cytoreduction may also benefit patients whose initial surgery is suboptimal, especially if the first procedure was performed by a surgeon unfamiliar with the disease. Secondary cytoreduction can increase survival in patients with low-volume disease and a long disease-free interval. All of these procedures should be performed by a specialist trained in ovarian cancer surgery.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Mark T. Wakabayashi, MD, MPH, Department of Gynecologic Oncology, Division of Surgery, City of Hope, 1500 East Duarte Road, Duarte, CA 91010-3000. E-mail: mwakabayashi@coh.org

Disclosure: Kerrin G. Robinson, MA, has disclosed no relevant financial relationships.

  • 1.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2.

    Ozols RF, Rubin SC, Thomas GM. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, et al., eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:916.

    • Search Google Scholar
    • Export Citation
  • 3.

    Piver MS, Fanning J, Sprance HE. Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery. J Surg Oncol 1991;48:3944.

    • Search Google Scholar
    • Export Citation
  • 4.

    McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.

    • Search Google Scholar
    • Export Citation
  • 5.

    Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 6.

    Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82:489497.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ozols RF, Bundy BN, Greer BE. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:31943200.

    • Search Google Scholar
    • Export Citation
  • 8.

    Prefontaine M, Gelfand AT, Donovan JT. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 1994;55:8790.

    • Search Google Scholar
    • Export Citation
  • 9.

    Gordon AN, Fleagle JT, Guthrie D. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:33123322.

    • Search Google Scholar
    • Export Citation
  • 10.

    Burger RA, Sill MW, Monk BJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:51655171.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hoskins WJ, Bundy BN, Thigpen JT. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159166.

    • Search Google Scholar
    • Export Citation
  • 12.

    Crawford SC, Vasey PA, Paul J. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005;23:88028811.

    • Search Google Scholar
    • Export Citation
  • 13.

    Berchuck A, Iversen ES, Lancaster JM. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910925.

    • Search Google Scholar
    • Export Citation
  • 14.

    Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269274.

  • 15.

    Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med 2004;351:25442546.

  • 16.

    Meigs JV. Tumors of the female pelvic organs. New York: Macmillan; 1934.

  • 17.

    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101104.

  • 18.

    Hoffman MS, Tebes SJ, Sayer RA. Extended cytoreduction of intraabdominal metastatic ovarian cancer in the left upper quadrant utilizing en bloc resection. Am J Obstet Gynecol 2007;197:209.e201204; discussion 209.e204–205.

    • Search Google Scholar
    • Export Citation
  • 19.

    Zivanovic O, Eisenhauer EL, Zhou Q. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2008;108:287292.

    • Search Google Scholar
    • Export Citation
  • 20.

    Eisenhauer EL, Abu-Rustum NR, Sonoda Y. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:10831090.

    • Search Google Scholar
    • Export Citation
  • 21.

    Manci N, Bellati F, Muzii L. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data. Ann Surg Oncol 2006;13:17171723.

    • Search Google Scholar
    • Export Citation
  • 22.

    Magtibay PM, Adams PB, Silverman MB. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 2006;102:369374.

  • 23.

    Hoffman MS, Griffin D, Tebes S. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 2005;193:582586; discussion 586–588.

    • Search Google Scholar
    • Export Citation
  • 24.

    Mourton SM, Temple LK, Abu-Rustum NR. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 2005;99:608614.

    • Search Google Scholar
    • Export Citation
  • 25.

    Takahashi O, Tanaka T. Intestinal surgery in advanced ovarian cancer. Curr Opin Obstet Gynecol 2007;19:1014.

  • 26.

    Hertel H, Diebolder H, Herrmann J. Is the decision for colorectal resection justified by histopathologic findings: a prospective study of 100 patients with advanced ovarian cancer. Gynecol Oncol 2001;83:481484.

    • Search Google Scholar
    • Export Citation
  • 27.

    Chi DS, Diaz JP, Jarnagin WR. Distal partial gastrectomy and gastrojejunal anastomosis for recurrent ovarian cancer. Gynecol Oncol 2007;104:3336.

    • Search Google Scholar
    • Export Citation
  • 28.

    Chi DS, Temkin SM, Abu-Rustum NR. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol 2002;87:138142.

    • Search Google Scholar
    • Export Citation
  • 29.

    Aletti GD, Dowdy SC, Podratz KC. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006;100:283287.

    • Search Google Scholar
    • Export Citation
  • 30.

    Cliby W, Dowdy S, Feitoza SS. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 2004;94:655660.

  • 31.

    Scholz HS, Tasdemir H, Hunlich T. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 2007;106:591595.

    • Search Google Scholar
    • Export Citation
  • 32.

    Winter WE III, Maxwell GL, Tian C. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:36213627.

    • Search Google Scholar
    • Export Citation
  • 33.

    Eisenkop SM, Spirtos NM, Friedman RL. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90:390396.

    • Search Google Scholar
    • Export Citation
  • 34.

    Bristow RE, Tomacruz RS, Armstrong DK. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:12481259.

    • Search Google Scholar
    • Export Citation
  • 35.

    Monk BJ, Disaia PJ. What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate. Int J Gynecol Cancer 2005;15 Suppl 3:199205.

    • Search Google Scholar
    • Export Citation
  • 36.

    du Bois A, Quinn M, Thigpen T. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7viii12.

    • Search Google Scholar
    • Export Citation
  • 37.

    Bristow RE, Montz FJ, Lagasse LD. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278287.

    • Search Google Scholar
    • Export Citation
  • 38.

    Salani R, Axtell A, Gerardi M. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008;108:271275.

    • Search Google Scholar
    • Export Citation
  • 39.

    Weide R, Arndt M, Pandorf A. Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival. Onkologie 2007;30:611617.

    • Search Google Scholar
    • Export Citation
  • 40.

    Chi DS, Franklin CC, Levine DA. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004;94:650654.

    • Search Google Scholar
    • Export Citation
  • 41.

    Le T, Krepart GV, Lotocki RJ. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67:208214.

    • Search Google Scholar
    • Export Citation
  • 42.

    Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J Clin Oncol 2007;25:41684170.

    • Search Google Scholar
    • Export Citation
  • 43.

    Onda T, Matsumoto K, Shibata T. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study JCOG0602. Jpn J Clin Oncol 2008;38:7477.

    • Search Google Scholar
    • Export Citation
  • 44.

    Chi DS, Eisenhauer EL, Lang J. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559564.

    • Search Google Scholar
    • Export Citation
  • 45.

    Brockbank EC, Ind TE, Barton DP. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 2004;14:4250.

    • Search Google Scholar
    • Export Citation
  • 46.

    Arits AH, Stoot JE, Botterweck AA. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2007.

    • Search Google Scholar
    • Export Citation
  • 47.

    Goodman HM, Harlow BL, Sheets EE. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992;46:367371.

    • Search Google Scholar
    • Export Citation
  • 48.

    Curtin JP, Malik R, Venkatraman ES. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:912.

  • 49.

    Naik R, Nordin A, Cross PA. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171175.

    • Search Google Scholar
    • Export Citation
  • 50.

    Zang RY, Zhang ZY, Cai SM. Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res 1999;18:449454.

  • 51.

    Munkarah AR, Hallum AV III, Morris M. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:1317.

    • Search Google Scholar
    • Export Citation
  • 52.

    Liu PC, Benjamin I, Morgan MA. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:48.

  • 53.

    Schwartz PE. Cytoreductive surgery for the management of stage IV ovarian cancer. Gynecol Oncol 1997;64:13.

  • 54.

    Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103108.

    • Search Google Scholar
    • Export Citation
  • 55.

    Pomel C, Jeyarajah A, Oram D. Cytoreductive surgery in ovarian cancer. Cancer Imaging 2007;7:210215.

  • 56.

    Everett EN, Heuser CC, Pastore LM. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 2005;193:568574; discussion 574–566.

    • Search Google Scholar
    • Export Citation
  • 57.

    Risum S, Hogdall C, Loft A. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography—a prospective study. Gynecol Oncol 2008;108:265270.

    • Search Google Scholar
    • Export Citation
  • 58.

    Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest 2004;57:153156.

    • Search Google Scholar
    • Export Citation
  • 59.

    Axtell AE, Lee MH, Bristow RE. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25:384389.

    • Search Google Scholar
    • Export Citation
  • 60.

    Bristow RE, Simpkins F, Pannu HK. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol 2002;85:196200.

    • Search Google Scholar
    • Export Citation
  • 61.

    Bland AE, Everett EN, Pastore LM. Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy. Int J Gynecol Cancer 2007;18:629636.

    • Search Google Scholar
    • Export Citation
  • 62.

    Bristow RE, Duska LR, Lambrou NC. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:15321540.

    • Search Google Scholar
    • Export Citation
  • 63.

    Aletti GD, Dowdy SC, Gostout BS. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:7785.

    • Search Google Scholar
    • Export Citation
  • 64.

    Janda M, Youlden DR, Baade PD. Elderly patients with stage III or IV ovarian cancer: should they receive standard care? Int J Gynecol Cancer 2007.

    • Search Google Scholar
    • Export Citation
  • 65.

    Uyar D, Frasure HE, Markman M. Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer. Gynecol Oncol 2005;98:403408.

    • Search Google Scholar
    • Export Citation
  • 66.

    Susini T, Amunni G, Busi E. Ovarian cancer in the elderly: feasibility of surgery and chemotherapy in 89 geriatric patients. Int J Gynecol Cancer 2007;17:581588.

    • Search Google Scholar
    • Export Citation
  • 67.

    Aletti GD, Santillan A, Eisenhauer EL. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007;107:99106.

    • Search Google Scholar
    • Export Citation
  • 68.

    van der Burg ME, van Lent M, Buyse M. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 69.

    Rose PG, Nerenstone S, Brady MF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:24892497.

  • 70.

    Bristow RE, Eisenhauer EL, Santillan A. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480490.

    • Search Google Scholar
    • Export Citation
  • 71.

    Colombo PE, Mourregot A, Fabbro M. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2008.

    • Search Google Scholar
    • Export Citation
  • 72.

    Morrison J, Swanton A, Collins S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2007:CD005343.

    • Search Google Scholar
    • Export Citation
  • 73.

    Coleman RL, Gershenson DM. Neoplastic Diseases of the Ovary. 5th ed. Philadelphia: Mosby; 2007.

  • 74.

    Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004;95:273280.

  • 75.

    Santillan A, Karam AK, Li AJ. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007;104:686690.

    • Search Google Scholar
    • Export Citation
  • 76.

    Salani R, Santillan A, Zahurak ML. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109:685691.

    • Search Google Scholar
    • Export Citation
  • 77.

    Benedetti Panici P, De Vivo A, Bellati F. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 2007;14:11361142.

    • Search Google Scholar
    • Export Citation
  • 78.

    Pfisterer J, Harter P, Canzler U. The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl 3):195198.

  • 79.

    Tebes SJ, Sayer RA, Palmer JM. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007;106:482487.

    • Search Google Scholar
    • Export Citation
  • 80.

    Zang RY, Li ZT, Tang J. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004;100:11521161.

    • Search Google Scholar
    • Export Citation
  • 81.

    Gungor M, Ortac F, Arvas M. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 2005;97:7479.

  • 82.

    Hauspy J, Covens A. Cytoreductive surgery for recurrent ovarian cancer. Curr Opin Obstet Gynecol 2007;19:1521.

  • 83.

    Diaz-Montes TP, Bristow RE. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep 2005;7:451458.

  • 84.

    Karam AK, Santillan A, Bristow RE. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 2007;104:377380.

    • Search Google Scholar
    • Export Citation
  • 85.

    Eisenkop SM, Spirtos NM, Montag TW. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203209.

    • Search Google Scholar
    • Export Citation
  • 86.

    Kehoe S, Powell J, Wilson S. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994;70:10141017.

    • Search Google Scholar
    • Export Citation
  • 87.

    Carney ME, Lancaster JM, Ford C. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:3642.

    • Search Google Scholar
    • Export Citation
  • 88.

    Aletti GD, Gostout BS, Podratz KC. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006;100:3337.

    • Search Google Scholar
    • Export Citation
  • 89.

    Engelen MJ, Kos HE, Willemse PH. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589598.

    • Search Google Scholar
    • Export Citation
  • 90.

    Paulsen T, Kjaerheim K, Kaern J. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16(Suppl 1):1117.

    • Search Google Scholar
    • Export Citation
  • 91.

    Bristow RE, Zahurak ML, del Carmen MG. Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 2004;93:353360.

  • 92.

    Vernooij F, Heintz P, Witteveen E. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007;105:801812.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 124 79 3
PDF Downloads 72 56 3
EPUB Downloads 0 0 0